Cost-effectiveness of ultra-low-dose quadruple combination therapy for high blood pressure
Authors' conclusion
Quadpill in comparison with monotherapy is comparably cost-effective for short-term BP lowering. In the long-term, quadpill therapy is likely to be cost-effective.
Study context
- Population
- People with hypertension, untreated or receiving monotherapy
- Comparison
- Quadpill vs irbesartan 150 mg monotherapy
- Primary endpoint
- Incremental cost-effectiveness ratios (ICERs): cost per mm Hg SBP reduction (within-trial) and modelled cost per QALY
- Follow-up
- 3 months (BP); lifetime (QALY)
Methodological detailspreplanned, cost-effectiveness and cost-utility analysis, lifetime model
- Preplanned
- Cost-effectiveness and cost-utility analysis
- Lifetime model
Primary result
As reported in the abstract
- 3 months; no clear difference
- cost per mm Hg blood pressure (BP) lowering $A10 per mm Hg per person (95% UI $A −18 to $A37)
- Lifetime model
- mean incremental cost $A265 per person (95% UI $A166 to $A357)
- Lifetime model
- mean quality-adjusted life year (QALYs) gained 0.02 QALYs per person (95% UI 0.01–0.03)
- Base case; cost-effective
- ICER $A14 006 per QALY
Original publication
Cost-effectiveness of ultra-low-dose quadruple combination therapy for high blood pressure. Heart. Published 26 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →